Tags

Type your tag names separated by a space and hit enter

The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans.
Eur J Nutr. 2004 Aug; 43(4):205-20.EJ

Abstract

BACKGROUND

The antiatherogenic activity of pomegranate juice has been attributed to its antioxidant polyphenols. The most potent in vitro antioxidant polyphenol from this juice is the ellagitannin punicalagin. However, the bioavailability of ellagitannins, including punicalagin, has not been previously described in humans.

AIM OF THE STUDY

The present work aims to evaluate, in healthy humans, the bioavailability and metabolism of pomegranate juice ellagitannins, to assess their effect on several blood parameters (including cardiovascular risk disease markers) and to compare the antioxidant activity of punicalagin with that of the in vivo generated metabolites.

DESIGN

Six healthy subjects (four men and two women) consumed 1 L of pomegranate juice daily (5.58 g/L polyphenols, including 4.37 g/L punicalagin isomers) for 5 days. The polyphenols and the in vivo generated metabolites were measured by HPLC-DAD-MS-MS. Fourteen haematological and twenty serobiochemical parameters including LDL, HDL and VLDL as well as cholesterol and triglycerides in each lipoprotein were evaluated. In vitro antioxidant activity of plasma (ABTS and FRAP assays) and urine (ABTS and DPPH) were determined.

RESULTS

Neither punicalagin nor ellagic acid present in the juice were detected in both plasma and urine. Three microbial ellagitannin-derived metabolites were detected: 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one glucuronide, an unidentified aglycone (tentatively, trihydroxy-6H-dibenzo[b,d]pyran-6-one) and hydroxy-6-H-dibenzo[b,d]pyran-6-one glucuronide. These metabolites could reach up to 18.6 microM in plasma, although a large inter-individual variability was observed. In urine, the same metabolites and their corresponding aglycones became evident after 1 day of juice consumption. Total urine excretion of metabolites ranged from 0.7 to 52.7% regarding the ingested punicalagin. No relevant effect was observed on any blood parameter. The metabolites did not show significant antioxidant activity compared to punicalagin from pomegranate juice.

CONCLUSIONS

The potential systemic biological effects of pomegranate juice ingestion should be attributed to the colonic microflora metabolites rather than to the polyphenols present in the juice.

Authors+Show Affiliations

Cerdá B
Research Group on Quality, Safety and Bioactivity of Plant Foods, Department Food Science and Technology, CEBAS-CSIC, 164, 30100, Espinardo (Murcia), Spain.
Espín JC
No affiliation info available
Parra S
No affiliation info available
Martínez P
No affiliation info available
Tomás-Barberán FA
No affiliation info available

MeSH

AdultAntioxidantsBacteria, AnaerobicBeveragesBiological AvailabilityChromatography, High Pressure LiquidColonFemaleFermentationGas Chromatography-Mass SpectrometryHumansHydrolyzable TanninsIntestinal AbsorptionLythraceaeMaleNutritive Value

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15309440

Citation

Cerdá, Begoña, et al. "The Potent in Vitro Antioxidant Ellagitannins From Pomegranate Juice Are Metabolised Into Bioavailable but Poor Antioxidant hydroxy-6H-dibenzopyran-6-one Derivatives By the Colonic Microflora of Healthy Humans." European Journal of Nutrition, vol. 43, no. 4, 2004, pp. 205-20.
Cerdá B, Espín JC, Parra S, et al. The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans. Eur J Nutr. 2004;43(4):205-20.
Cerdá, B., Espín, J. C., Parra, S., Martínez, P., & Tomás-Barberán, F. A. (2004). The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans. European Journal of Nutrition, 43(4), 205-20.
Cerdá B, et al. The Potent in Vitro Antioxidant Ellagitannins From Pomegranate Juice Are Metabolised Into Bioavailable but Poor Antioxidant hydroxy-6H-dibenzopyran-6-one Derivatives By the Colonic Microflora of Healthy Humans. Eur J Nutr. 2004;43(4):205-20. PubMed PMID: 15309440.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans. AU - Cerdá,Begoña, AU - Espín,Juan Carlos, AU - Parra,Soledad, AU - Martínez,Pedro, AU - Tomás-Barberán,Francisco A, Y1 - 2004/01/06/ PY - 2003/07/30/received PY - 2003/08/26/accepted PY - 2004/8/17/pubmed PY - 2004/12/31/medline PY - 2004/8/17/entrez SP - 205 EP - 20 JF - European journal of nutrition JO - Eur J Nutr VL - 43 IS - 4 N2 - BACKGROUND: The antiatherogenic activity of pomegranate juice has been attributed to its antioxidant polyphenols. The most potent in vitro antioxidant polyphenol from this juice is the ellagitannin punicalagin. However, the bioavailability of ellagitannins, including punicalagin, has not been previously described in humans. AIM OF THE STUDY: The present work aims to evaluate, in healthy humans, the bioavailability and metabolism of pomegranate juice ellagitannins, to assess their effect on several blood parameters (including cardiovascular risk disease markers) and to compare the antioxidant activity of punicalagin with that of the in vivo generated metabolites. DESIGN: Six healthy subjects (four men and two women) consumed 1 L of pomegranate juice daily (5.58 g/L polyphenols, including 4.37 g/L punicalagin isomers) for 5 days. The polyphenols and the in vivo generated metabolites were measured by HPLC-DAD-MS-MS. Fourteen haematological and twenty serobiochemical parameters including LDL, HDL and VLDL as well as cholesterol and triglycerides in each lipoprotein were evaluated. In vitro antioxidant activity of plasma (ABTS and FRAP assays) and urine (ABTS and DPPH) were determined. RESULTS: Neither punicalagin nor ellagic acid present in the juice were detected in both plasma and urine. Three microbial ellagitannin-derived metabolites were detected: 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one glucuronide, an unidentified aglycone (tentatively, trihydroxy-6H-dibenzo[b,d]pyran-6-one) and hydroxy-6-H-dibenzo[b,d]pyran-6-one glucuronide. These metabolites could reach up to 18.6 microM in plasma, although a large inter-individual variability was observed. In urine, the same metabolites and their corresponding aglycones became evident after 1 day of juice consumption. Total urine excretion of metabolites ranged from 0.7 to 52.7% regarding the ingested punicalagin. No relevant effect was observed on any blood parameter. The metabolites did not show significant antioxidant activity compared to punicalagin from pomegranate juice. CONCLUSIONS: The potential systemic biological effects of pomegranate juice ingestion should be attributed to the colonic microflora metabolites rather than to the polyphenols present in the juice. SN - 1436-6207 UR - https://www.unboundmedicine.com/medline/citation/15309440/The_potent_in_vitro_antioxidant_ellagitannins_from_pomegranate_juice_are_metabolised_into_bioavailable_but_poor_antioxidant_hydroxy_6H_dibenzopyran_6_one_derivatives_by_the_colonic_microflora_of_healthy_humans_ DB - PRIME DP - Unbound Medicine ER -